Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BRM 421

Next Previous
Drug Profile

BRM 421

Alternative Names: BRM 421; GPN 00136; PDSP

Latest Information Update: 07 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MacKay Memorial Hospital
  • Developer BRIM Biotechnology
  • Class Peptides
  • Mechanism of Action Cell proliferation stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Dry eyes
  • Preclinical Osteoarthritis
  • No development reported Alopecia; Corneal injuries

Most Recent Events

  • 04 Dec 2024 BRIM Biotechnology plans a phase I trial for Osteoarthritis (Intra-articular, Injection) in 2025 (BRIM Biotechnology pipeline, December 2024)
  • 30 Dec 2023 BRIM Biotechnology completes a phase III trial in Dry eyes (In the elderly, In adults) in USA (Ophthalmic, Solution) (NCT05695781)
  • 27 Feb 2023 Phase-III clinical trials in Dry eyes (In the elderly, In adults) in USA (Ophthalmic) (NCT05695781)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top